The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Feb. 18, 2025
Filed:
Dec. 24, 2020
Astellas Pharma Inc., Tokyo, JP;
Kotobuki Pharmaceutical Co., Ltd., Nagano, JP;
Hideyuki Watanabe, Tokyo, JP;
Yohei Seki, Tokyo, JP;
Keiichiro Okuyama, Tokyo, JP;
Kazuo Kurosawa, Tokyo, JP;
Osamu Ikeda, Tokyo, JP;
Hiroshi Tomiyama, Nagano, JP;
Yoshinori Iwai, Nagano, JP;
Akihiko Nakamura, Nagano, JP;
Kozo Miyasaka, Nagano, JP;
Astellas Pharma Inc., Tokyo, JP;
KOTOBUKI PHARMACEUTICAL CO., LTD., Nagano, JP;
Abstract
A compound useful as an active ingredient of a pharmaceutical composition for treatment of cancer related to activation of immune cells or cancer having resistance to anti-PD-1 antibody/anti-PD-L1 antibody therapy is provided. The present inventors have conducted studies on a compound useful as an active ingredient of a pharmaceutical composition for treatment of cancer related to activation of immune cells or cancer having resistance to anti-PD-1 antibody/anti-PD-L1 antibody therapy, and found that a pyridazinyl-thiazolecarboxamide compound has DGK ξ (DGKzeta) inhibitory effect, leading to completion of the present invention. The pyridazinyl-thiazolecarboxamide compound of the present invention has DGK ξ inhibitory effect, and can be used as a therapeutic agent for treatment of cancer related to activation of immune cells or cancer having resistance to anti-PD-1 antibody/anti-PD-L1 antibody therapy.